Free Trial

Avidity Biosciences (RNA) Competitors

Avidity Biosciences logo
$36.27 +3.06 (+9.21%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$37.19 +0.92 (+2.54%)
As of 07/25/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RNA vs. GMAB, MRNA, RDY, QGEN, VTRS, ASND, VRNA, BBIO, BPMC, and ROIV

Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

Avidity Biosciences vs. Its Competitors

Genmab A/S (NASDAQ:GMAB) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Genmab A/S has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genmab A/S currently has a consensus price target of $37.80, suggesting a potential upside of 61.54%. Avidity Biosciences has a consensus price target of $66.35, suggesting a potential upside of 82.94%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Avidity Biosciences
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

Genmab A/S has a net margin of 35.11% compared to Avidity Biosciences' net margin of -4,136.00%. Genmab A/S's return on equity of 18.08% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S35.11% 18.08% 14.52%
Avidity Biosciences -4,136.00%-26.96%-24.57%

Genmab A/S has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.12B4.81$1.14B$1.7613.30
Avidity Biosciences$10.90M401.03-$322.30M-$3.00-12.09

In the previous week, Avidity Biosciences had 1 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Avidity Biosciences and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.27 beat Avidity Biosciences' score of 0.89 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avidity Biosciences
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Genmab A/S beats Avidity Biosciences on 10 of the 16 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNA vs. The Competition

MetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.00B$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-12.0921.1828.1020.05
Price / Sales401.03286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book3.048.378.665.87
Net Income-$322.30M-$55.19M$3.25B$258.55M
7 Day Performance7.43%5.88%4.22%3.73%
1 Month Performance21.59%17.33%10.51%11.75%
1 Year Performance-24.66%4.42%34.40%18.03%

Avidity Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNA
Avidity Biosciences
2.1597 of 5 stars
$36.27
+9.2%
$66.35
+82.9%
-18.9%$4.00B$10.90M-12.09190News Coverage
High Trading Volume
GMAB
Genmab A/S
4.0786 of 5 stars
$21.69
-0.9%
$37.80
+74.3%
-16.8%$14.04B$3.12B15.742,682Positive News
MRNA
Moderna
4.2999 of 5 stars
$30.97
-0.9%
$46.61
+50.5%
-71.6%$12.09B$3.24B-3.555,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7326 of 5 stars
$14.57
+0.6%
$16.95
+16.4%
-9.3%$12.09B$3.81B21.9427,811Earnings Report
QGEN
QIAGEN
3.7199 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+26.1%$10.75B$1.98B120.495,765Positive News
Analyst Downgrade
Analyst Revision
VTRS
Viatris
2.368 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-20.0%$10.42B$14.74B3.5832,000
ASND
Ascendis Pharma A/S
3.6186 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+24.6%$10.39B$393.54M-26.751,017Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.8275 of 5 stars
$104.90
flat
$109.00
+3.9%
+375.4%$8.93B$42.28M-52.4530Positive News
BBIO
BridgeBio Pharma
4.6357 of 5 stars
$45.90
-1.3%
$61.50
+34.0%
+73.4%$8.83B$221.90M0.00400Analyst Downgrade
BPMC
Blueprint Medicines
0.9484 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Positive News
Upcoming Earnings
ROIV
Roivant Sciences
2.649 of 5 stars
$11.48
+0.3%
$16.50
+43.7%
+7.5%$7.78B$29.05M0.00860News Coverage
Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:RNA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners